What Is GLP 3 (Reta)?

GLP 3 (Reta), also identified by the development code LY3437943, is a synthetic lipidated peptide designed as a triple agonist of the GIP, GLP-1 and glucagon receptors.

The compound is studied in laboratory settings to examine multi-receptor incretin signaling, receptor activation and related metabolic pathways. Its 39-amino-acid structure includes a fatty-acid modification intended to support albumin binding and extended experimental activity.

GLP 3 (Reta) remains an investigational research compound and is not an approved medicine. It is supplied exclusively for legitimate in-vitro laboratory and analytical research.

Research Context

GLP 3 (Reta) may be used in controlled research examining:

• GIP, GLP-1 and glucagon receptor binding
• Receptor-mediated cAMP signaling
• Incretin signaling in laboratory cell models
• Comparative single-, dual- and triple-receptor agonist research
• Metabolic-flux and energy-expenditure studies in research models
• Albumin-binding and experimental stability characterization
• Structure–activity relationships of engineered incretin peptides

This information describes research context only and must not be presented as medical, treatment or human-use guidance.